APEX1 and breast carcinoma: Although high APE1 has been demonstrated in multiple tumour types and associated with poor prognosis or response to therapy [9, 29], in a recent study in a large cohort of breast cancers (n=1285), we observed that APE1 was low in about 50% of tumours.